View in EDS

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

Saved in:
Bibliographic Details
Title: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.
Authors: Weeden T; Dyne Therapeutics Inc, Waltham, MA, USA., Picariello T; Dyne Therapeutics Inc, Waltham, MA, USA., Quinn B; Dyne Therapeutics Inc, Waltham, MA, USA., Spring S; Dyne Therapeutics Inc, Waltham, MA, USA.; Pheon Therapeutics, Cambridge, MA, USA., Shen PY; Dyne Therapeutics Inc, Waltham, MA, USA., Qiu Q; Dyne Therapeutics Inc, Waltham, MA, USA., Vieira BF; Dyne Therapeutics Inc, Waltham, MA, USA., Schlaefke L; Dyne Therapeutics Inc, Waltham, MA, USA., Russo RJ; Dyne Therapeutics Inc, Waltham, MA, USA., Chang YA; Dyne Therapeutics Inc, Waltham, MA, USA., Cui J; Dyne Therapeutics Inc, Waltham, MA, USA., Yao M; Dyne Therapeutics Inc, Waltham, MA, USA., Wen A; Dyne Therapeutics Inc, Waltham, MA, USA.; Rona Therapeutics, Shanghai, China., Hsia N; Dyne Therapeutics Inc, Waltham, MA, USA., Evron T; Dyne Therapeutics Inc, Waltham, MA, USA., Ovington K; Dyne Therapeutics Inc, Waltham, MA, USA.; 4:59 NewCo, a 5AM Ventures Company, Boston, MA, USA., Tsai PN; Dyne Therapeutics Inc, Waltham, MA, USA.; Generation Bio, Cambridge, MA, USA., Yoder N; Dyne Therapeutics Inc, Waltham, MA, USA., Lan B; Dyne Therapeutics Inc, Waltham, MA, USA.; Summation Bio, Cambridge, MA, USA., Venkatesan R; Dyne Therapeutics Inc, Waltham, MA, USA., Hall J; Dyne Therapeutics Inc, Waltham, MA, USA., Desjardins CA; Dyne Therapeutics Inc, Waltham, MA, USA., Qatanani M; Dyne Therapeutics Inc, Waltham, MA, USA.; Scholar Rock, Cambridge, MA, USA., Hilderbrand S; Dyne Therapeutics Inc, Waltham, MA, USA., Najim J; Dyne Therapeutics Inc, Waltham, MA, USA., Tang Z; University of Rochester Medical Center, Rochester, NY, USA., Tanner MK; University of Rochester Medical Center, Rochester, NY, USA., Subramanian R; Dyne Therapeutics Inc, Waltham, MA, USA., Thornton CA; University of Rochester Medical Center, Rochester, NY, USA., Ibraghimov-Beskrovnaya O; Dyne Therapeutics Inc, Waltham, MA, USA., Zanotti S; Dyne Therapeutics Inc, Waltham, MA, USA. szanotti@dyne-tx.com.
Source: Communications medicine [Commun Med (Lond)] 2025 Jan 18; Vol. 5 (1), pp. 22. Date of Electronic Publication: 2025 Jan 18.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39827287
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Weeden+T%22">Weeden T</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Picariello+T%22">Picariello T</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Quinn+B%22">Quinn B</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Spring+S%22">Spring S</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; Pheon Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shen+PY%22">Shen PY</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Qiu+Q%22">Qiu Q</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Vieira+BF%22">Vieira BF</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Schlaefke+L%22">Schlaefke L</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Russo+RJ%22">Russo RJ</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chang+YA%22">Chang YA</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cui+J%22">Cui J</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yao+M%22">Yao M</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wen+A%22">Wen A</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; Rona Therapeutics, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Hsia+N%22">Hsia N</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Evron+T%22">Evron T</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ovington+K%22">Ovington K</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; 4:59 NewCo, a 5AM Ventures Company, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+PN%22">Tsai PN</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; Generation Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yoder+N%22">Yoder N</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lan+B%22">Lan B</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; Summation Bio, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Venkatesan+R%22">Venkatesan R</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hall+J%22">Hall J</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Desjardins+CA%22">Desjardins CA</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Qatanani+M%22">Qatanani M</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.; Scholar Rock, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hilderbrand+S%22">Hilderbrand S</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Najim+J%22">Najim J</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tang+Z%22">Tang Z</searchLink>; University of Rochester Medical Center, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Tanner+MK%22">Tanner MK</searchLink>; University of Rochester Medical Center, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Subramanian+R%22">Subramanian R</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Thornton+CA%22">Thornton CA</searchLink>; University of Rochester Medical Center, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ibraghimov-Beskrovnaya+O%22">Ibraghimov-Beskrovnaya O</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Zanotti+S%22">Zanotti S</searchLink>; Dyne Therapeutics Inc, Waltham, MA, USA. szanotti@dyne-tx.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918250414506676%22">Communications medicine</searchLink> [Commun Med (Lond)] 2025 Jan 18; Vol. 5 (1), pp. 22. <i>Date of Electronic Publication: </i>2025 Jan 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Portfolio%22">Nature Portfolio </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918250414506676 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2730-664X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222730664X%22">2730664X </searchLink><i>NLM ISO Abbreviation: </i>Commun Med (Lond) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39827287
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s43856-025-00733-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 22
    Titles:
      – TitleFull: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Weeden T
      – PersonEntity:
          Name:
            NameFull: Picariello T
      – PersonEntity:
          Name:
            NameFull: Quinn B
      – PersonEntity:
          Name:
            NameFull: Spring S
      – PersonEntity:
          Name:
            NameFull: Shen PY
      – PersonEntity:
          Name:
            NameFull: Qiu Q
      – PersonEntity:
          Name:
            NameFull: Vieira BF
      – PersonEntity:
          Name:
            NameFull: Schlaefke L
      – PersonEntity:
          Name:
            NameFull: Russo RJ
      – PersonEntity:
          Name:
            NameFull: Chang YA
      – PersonEntity:
          Name:
            NameFull: Cui J
      – PersonEntity:
          Name:
            NameFull: Yao M
      – PersonEntity:
          Name:
            NameFull: Wen A
      – PersonEntity:
          Name:
            NameFull: Hsia N
      – PersonEntity:
          Name:
            NameFull: Evron T
      – PersonEntity:
          Name:
            NameFull: Ovington K
      – PersonEntity:
          Name:
            NameFull: Tsai PN
      – PersonEntity:
          Name:
            NameFull: Yoder N
      – PersonEntity:
          Name:
            NameFull: Lan B
      – PersonEntity:
          Name:
            NameFull: Venkatesan R
      – PersonEntity:
          Name:
            NameFull: Hall J
      – PersonEntity:
          Name:
            NameFull: Desjardins CA
      – PersonEntity:
          Name:
            NameFull: Qatanani M
      – PersonEntity:
          Name:
            NameFull: Hilderbrand S
      – PersonEntity:
          Name:
            NameFull: Najim J
      – PersonEntity:
          Name:
            NameFull: Tang Z
      – PersonEntity:
          Name:
            NameFull: Tanner MK
      – PersonEntity:
          Name:
            NameFull: Subramanian R
      – PersonEntity:
          Name:
            NameFull: Thornton CA
      – PersonEntity:
          Name:
            NameFull: Ibraghimov-Beskrovnaya O
      – PersonEntity:
          Name:
            NameFull: Zanotti S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 01
              Text: 2025 Jan 18
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2730-664X
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Communications medicine
              Type: main
ResultId 1